AFMD Affimed N.V.

Affimed NV is a clinical-stage biopharmaceutical company. It is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology to fight tumor cells.

As of 09/30/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Germany
Country of incorporation:  The Netherlands
IPO date:  09/12/2014
Outstanding shares:  123,419,772
Average volume:  1,402,556
Market cap:   $250,542,137
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BQQF5R2
Valuation   (See tab for details)
PE ratio:   -4.42
PB ratio:   1.87
PS ratio:   5.89
Return on equity:   -42.31%
Net income %:   -142.50%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy